Member Info for BuenaVista

Ah.

To get your thoughts on what? The Phase 1a Q3W data? Your voting intention? The price of fish?

Why did TP call?

SP back to where it was 4:30, Friday, and AS yet to speak.

@CTSFO, No. 120mg/m² was C3. No MTD was found in any of the seven cohorts up to 385mg/m² (RNS of 21 March).

What is this strange ACCR of which you speak oh wondrous Bot? Is it that Avacta are joining Automóvil Club de Costa Rica?

Moron

Could be SIPP trades. No limit there except earnings.

Full data release will be in the peer reviewed paper, Avacta's first pre|CISION peer reviewed paper. If it is ever published.

As far as I can see, Avacta's plans, as described in the RNS of 28 February (the infamous one) and the updated website, consist of nothing more than progressing AVA6000 in an admirably thorough way, getting AVA3996 to the submitting an IND/CTA application stage a year later than originally planned, and a lot of fluff (AS waffle) about whatever else might happen over the next 18 months to two years.

https://www.lse.co.uk/rns/AVCT/proposed-fundraise-to-progress-therapeutics-pa5q71zfw9lgspt.html

https://avacta.com/precision/pipeline/

I wonder how the DX expansion into Germany is going.

Corrected for you Bella. No need to thank me.

Now, what was that new position announcement I saw a couple of days ago on LinkedIn about...🤔

I don't know whether this pre|CISION™ ADC approach should be termed Search & Destroy or Belt & Braces. Nor how much more effective than pre|CISION™ alone it could be - PK, etc. data for pre|CISION™ will tell that.

One thing's for sure: it would be a lot more targetted than cleavable ADCs alone and that's perhaps the point as there are lot of invested resources already thrown at ADCs.

There was a lot in that review, too much to quote or even to point towards. But one takeaway I had was tha tthe toxic side effects are due to the warhead, irrespective of the mAb and what the mAb is targetted at. That means that either the warhead is active when attached to the mAb or, most commonly, the warhead is non-specifically cleaved off by enzymes or acidity and so is able to roam free within the body. pre|CISION's exquisite specificity is a whole step change up in reducing such toxicity.

Tookanarkman wrote "What does “AVA6000 distributes rapidly with a t1/2 of 45 min” actually mean? "

"AVA6000" means Avacta's drug undergoing Phase 1a trial

"distributes rapidly" means distributes rapidly

"t1/2" means half-life

"45 min" means three quaters of an hour

As I remember, AS said there was a problem with the practical application of FAPi-PET in both access (only available from a few places) and timeliness (short half-life of the radioactive diagnostics).

A good, but long, review of ADC toxicity:

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913659/

"...escalating AVA6000 doses from 80mg/m2 (51 mg/m2 doxorubicin; molar equivalent, 0.675) to 385 mg/m2 (260 mg/m2 doxorubicin equivalent)."

Anyone else spotted Avacta's obligatory mistake? Having told everyone that 80mg/m² of AVA6000 was equivalent to 54mg/m² of doxorubicin from the start they have put 51mg/m² in the abstract. Again, Avacta still operationally useless.

Free Ribena bottle with every error identified.

Correct. Poster will have tables, graphs, bells, whistles and everything.

Seems a bit of a mess. Having been involved in website maintenance myself, I know that it should be straightforward: you have a development (internal) server and a production (internet-facing) server; you play around on the development server until everything is working as you want it to; and then you copy everything over (publish) to the production server.

Https://avacta.com/wp-content/uploads/2024/04/Glossary.pdf